CDK Inhibition in HR-Positive, HER2-Negative Early-Stage Breast Cancer

home / case-based-roundtable-series / cdk-inhibition-in-hr-positive-her2-negative-early-stage-breast-cancer

This roundtable series considers the use of CDK4/6 inhibitors in patients with hormone receptor–positive, HER2-negative, early-stage breast cancer as discussed by participants at virtual live events.

Part 1: Abemaciclib Shows Efficacy in High-Risk Early Breast Cancer

Part 1: Abemaciclib Shows Efficacy in High-Risk Early Breast Cancer

Targeted Oncology Staff
January 24th 2022

During a live virtual event, Lowell Hart, MD, discussed the results of the monarchE trial of abemaciclib in patients with node-positive, hormone receptor–positive, HER2-negative, high-risk early breast cancer.

Part 2: Recommending Abemaciclib for Early Breast Cancer Based on Ki67 Status

Part 2: Recommending Abemaciclib for Early Breast Cancer Based on Ki67 Status

Targeted Oncology Staff
February 2nd 2022

During a live virtual event, Lowell Hart, MD, discussed the findings of the monarchE trial of abemaciclib in high-risk patients with early breast cancer.

Abemaciclib Shows Long-Term IDFS Benefit in HR+, HER2- Breast Cancer

Abemaciclib Shows Long-Term IDFS Benefit in HR+, HER2- Breast Cancer

Manali A. Bhave, MD
March 7th 2022

Manali Bhave, MD, discusses the updated results of the MonarchE study of abemaciclib in patients with hormone receptor-positive, HER2-negative, breast cancer.

Management of HR+, HER2- Early-Stage Breast Cancer After Diagnosis

Management of HR+, HER2- Early-Stage Breast Cancer After Diagnosis

Jeffrey Aldrich, MD;Maisey Ratcliffe, MPH;Manali A. Bhave, MD
June 1st 2022

Physicians cover the options for a patient with hormone receptor–positive, HER2-negative, early-stage breast cancer, which course of action they would take, and the data supporting that choice.